Pacira Pharmaceuticals buy Royal Bank of Canada
Start price
31.07.24
/
50%
€19.10
Target price
31.07.25
€34.16
Performance (%)
-34.56%
Price
05.09.24
€13.10
Summary
This prediction is currently active. Massive losses of -34.56% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 31.07.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | -5.072% | -5.072% |
iShares Core DAX® | -3.429% | 5.085% |
iShares Nasdaq 100 | -6.121% | 0.593% |
iShares Nikkei 225® | -7.364% | 5.479% |
iShares S&P 500 | -4.366% | 2.019% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $42.00 to $37.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
01.03.24
01.03.24
€41.56
01.03.25
01.03.25
-48.09%
05.09.24
05.09.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€28.40
03.11.23
03.11.23
€54.04
03.11.24
03.11.24
-55.99%
05.09.24
05.09.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€27.40
03.10.23
03.10.23
€65.04
03.10.24
03.10.24
-50.37%
05.09.24
05.09.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€34.80
03.08.23
03.08.23
€62.07
03.08.24
03.08.24
-47.13%
04.08.24
04.08.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.00
01.03.23
01.03.23
€71.20
01.03.24
01.03.24
-34.50%
02.03.24
02.03.24